Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis

Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.

[1]  O. Sheils,et al.  Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion , 2015, BMC Cancer.

[2]  Yoshihisa Hagihara,et al.  Carbon nanotube–liposome supramolecular nanotrains for intelligent molecular-transport systems , 2012, Nature Communications.

[3]  A. Schömig.  Ticagrelor--is there need for a new player in the antiplatelet-therapy field? , 2009, The New England journal of medicine.

[4]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[5]  B. Johnston,et al.  The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer , 2015, International journal of cancer.

[6]  Yanhua Wang,et al.  Platelet P2Y12 Is Involved in Murine Pulmonary Metastasis , 2013, PloS one.

[7]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[8]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[9]  M. Nicolau,et al.  LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. , 2011, Cancer research.

[10]  H. Rammensee,et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. , 2012, Cancer research.

[11]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[12]  Erkki Ruoslahti,et al.  Targeting atherosclerosis by using modular, multifunctional micelles , 2009, Proceedings of the National Academy of Sciences.

[13]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[14]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[15]  Narayana M. Sekar,et al.  Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy , 2015, ACS nano.

[16]  M. Fritzler,et al.  The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). , 2012, Autoimmunity reviews.

[17]  B. Tesfamariam.  Involvement of platelets in tumor cell metastasis. , 2016, Pharmacology & therapeutics.

[18]  R. Zhao,et al.  Engineering the Assemblies of Biomaterial Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor Efficacy , 2013, Advances in Materials.

[19]  T. Ji,et al.  Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models , 2016 .

[20]  J. Fei,et al.  Rational assembly of a biointerfaced core@shell nanocomplex towards selective and highly efficient synergistic photothermal/photodynamic therapy. , 2015, Nanoscale.

[21]  M. Wojtukiewicz,et al.  Inhibition of platelet function: does it offer a chance of better cancer progression control? , 2007, Seminars in thrombosis and hemostasis.

[22]  Wassim Raffoul,et al.  A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response. , 2016, Cancer cell.

[23]  S. Offermanns,et al.  Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. , 2013, Cancer cell.

[24]  A. Molinari,et al.  Liposomes as nanomedical devices , 2015, International journal of nanomedicine.

[25]  B. Echtenacher,et al.  Lysis of tumor cells by natural killer cells in mice is impeded by platelets. , 1999, Cancer research.

[26]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[27]  M. Reiss,et al.  Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-β Type I Receptor Kinase In vivo , 2006, Clinical Cancer Research.